Oaktree Acquisition Corp III Life Sciences

1. 1

   Extension Amendment Proposal

   ManagementBoard: FOR

   Approve amendments to OAC’s Memorandum and Articles of Association extending the Business Combination termination date from October 25, 2026 to November 25, 2026, while permitting up to six additional one-month extensions, requested by the Sponsor and approved by the Board without another shareholder vote, through no later than May 25, 2027. The amendments also preserve public shareholders’ redemption rights in specified circumstances.

   More detail

   Proposal 1 asks shareholders to amend OAC’s governing documents so the company can continue pursuing an initial Business Combination beyond the existing October 25, 2026 deadline. The proposed amendment moves the initial deadline to November 25, 2026. It also authorizes the Board, without another shareholder vote, to extend the deadline monthly up to six additional times if the Sponsor makes a written request and the required advance notice is provided. The maximum possible deadline would be May 25, 2027, unless a Business Combination closes earlier. If no Business Combination occurs by the applicable deadline, the revised provision requires OAC to cease operations, redeem its Public Shares, and liquidate and dissolve subject to Cayman Islands law. The amendment separately preserves redemption opportunities if future amendments alter the timing or substance of public shareholders’ redemption rights. Management states that OAC believes it cannot complete a Business Combination by October 25, 2026 and would otherwise be forced to liquidate, making the extension necessary to preserve the opportunity to complete a transaction. Public shareholders may redeem shares if the extension is implemented, regardless of how they vote, with the indicated redemption price based on the Trust Account. The Board unanimously recommends a vote FOR, concluding that the additional time is in OAC’s and its shareholders’ best interests.

2. 2

   Adjournment Proposal

   ManagementBoard: FOR

   Approve adjournment of the Shareholder Meeting to a later date or indefinitely if needed to solicit additional proxies and votes because there are insufficient votes to approve the Extension Amendment Proposal, or if the Board otherwise determines adjournment is necessary.

   More detail

   Proposal 2 asks shareholders to authorize adjournment of the extraordinary general meeting to a later date or dates, or indefinitely, if circumstances warrant. The principal stated purpose is to permit further solicitation and voting if the shares represented at the meeting are insufficient to approve Proposal 1. The Board may also seek adjournment when it determines that doing so is otherwise necessary. The proposal is procedural and does not itself extend OAC’s Business Combination deadline or approve a Business Combination. It is intended to preserve flexibility if the vote count is inadequate or if public shareholders need additional time to reverse redemption requests. The proposal is conditional in practice because it would not be presented if the Extension Amendment Proposal is approved at the meeting. Approval requires an ordinary resolution, meaning at least a majority of votes cast by the relevant shareholders present or represented and entitled to vote. Abstentions and broker non-votes count toward quorum but do not constitute votes cast and therefore have no effect on approval. The Sponsor intends to vote its shares in favor, and the Board unanimously recommends a vote FOR the proposal as a means of facilitating approval of the extension if additional time becomes necessary.

Upcoming shareholder meetings at Oaktree Acquisition Corp III Life Sciences’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Oaktree Acquisition Corp III Life Sciences 2026 special meeting?

Oaktree Acquisition Corp III Life Sciences (OACC) holds its 2026 special shareholder meeting on Friday, October 16, 2026.

What is the record date for the Oaktree Acquisition Corp III Life Sciences 2026 meeting?

The record date for the Oaktree Acquisition Corp III Life Sciences 2026 meeting is Tuesday, September 22, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Oaktree Acquisition Corp III Life Sciences's 2026 meeting?

The board is presenting 7 director nominees at the Oaktree Acquisition Corp III Life Sciences 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Oaktree Acquisition Corp III Life Sciences 2026 meeting?

Shareholders will vote on 2 proposals at the Oaktree Acquisition Corp III Life Sciences 2026 meeting, each tagged with who proposed it and the board's recommendation.